Success Metrics

Clinical Success Rate
100.0%

Based on 11 completed trials

Completion Rate
100%(11/11)
Active Trials
0(0%)
Results Posted
9%(1 trials)

Phase Distribution

Ph phase_2
6
55%
Ph phase_1
3
27%
Ph early_phase_1
2
18%

Phase Distribution

5

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Early Phase 1First-in-human
2(18.2%)
Phase 1Safety & dosage
3(27.3%)
Phase 2Efficacy & side effects
6(54.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

11 of 11 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(11)

Detailed Status

Completed11

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 12 (18.2%)
Phase 13 (27.3%)
Phase 26 (54.5%)

Trials by Status

completed11100%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_1

Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists

NCT02126579
completedearly_phase_1

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

NCT01748747
completedphase_1

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

NCT00948961
completedearly_phase_1

Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery

NCT00470379
completedphase_1

Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists

NCT01737580
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT02126579Phase 1

Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists

Completed
NCT01748747Early Phase 1

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

Completed
NCT00948961Phase 1

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Completed
NCT00470379Early Phase 1

Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery

Completed
NCT01737580Phase 1

Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists

Completed
NCT00117923Phase 2

Study With a Topical Gel to Treat Common Warts in Adults

Completed
NCT00116662Phase 2

An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

Completed
NCT00114920Phase 2

Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults

Completed
NCT00117871Phase 2

Study With a Topical Gel to Treat Common Warts in Adults

Completed
NCT00115141Phase 2

Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults

Completed
NCT00116675Phase 2

Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11